Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA

A Marouf; N Molinari; D Sibon; A S Cottereau; S Kanoun; C Antoine; P E Debureaux; D Cavalieri; L M Fornecker; R O Casasnovas; C Herbaux; S Amorim; C Rossi; D Bouscary; P Brice; H Ghesquieres; J Tamburini; B Deau

doi:10.1111/bjh.18859

Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA

Br J Haematol. 2023 Jul;202(2):379-383. doi: 10.1111/bjh.18859. Epub 2023 May 16.

Authors

A Marouf^{1

2

3}, N Molinari⁴, D Sibon^{5

6}, A S Cottereau^{1

7}, S Kanoun⁸, C Antoine⁹, P E Debureaux¹⁰, D Cavalieri¹¹, L M Fornecker^{12

13}, R O Casasnovas^{14

15}, C Herbaux¹⁶, S Amorim¹⁷, C Rossi^{18

19

20}, D Bouscary^{1

2

21}, P Brice¹⁷, H Ghesquieres²², J Tamburini^{1

2

23}, B Deau^{1

2

3}

Affiliations

¹ Laboratoire U1163, Institut Imagine, Université Paris Cité, Inserm, Paris, France.
² Service Hématologie, AP-HP, Hôpital Cochin, Paris, France.
³ Groupe Hospitalier privé Ambroise Paré-Hartmann, Département Recherche Innovation, Neuilly-Sur-Seine, France.
⁴ IDESP, INSERM, PreMEdical INRIA, Univ Montpellier, CHU Montpellier, Montpellier, France.
⁵ Paris Est University, Créteil, France.
⁶ Service Hémopathies Lymphoïdes, AP-HP, Hôpital Henri Mondor, Créteil, France.
⁷ Service de Médecine Nucléaire, AP-HP, Hôpital Cochin, Paris, France.
⁸ Centre de Recherche Clinique de Toulouse, Team 9, Toulouse, France.
⁹ Lymphoma Academic Research Organization (LYSARC) Lymphoma Study Association Imaging, Hôpital Henri Mondor, Créteil, France.
¹⁰ Saint Louis Research Institute, INSERM U1160, Paris, France.
¹¹ Service Hématologie, CHRU Lille, Lille, France.
¹² Université de Strasbourg, INSERM S-1113, Strasbourg, France.
¹³ Service Hématologie, Cancéropôle Est, Strasbourg, France.
¹⁴ UFR des Sciences de Santé, INSERM UMR 1231 CHU Dijon, Dijon, France.
¹⁵ Service Hématologie, CHU Dijon, Dijon, France.
¹⁶ Service Hématologie, CHU Montpellier, Montpellier, France.
¹⁷ Service Hématologie, Hôpital Saint-Louis, Paris, France.
¹⁸ Department of Hematology, Dijon-Bourgogne University Hospital, Dijon, France.
¹⁹ INSERM Unit 1231, University of Burgundy Franche-Comté, Besancon, France.
²⁰ Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, California, USA.
²¹ Centre de Recherche des Cordeliers, INSERM U1016, Université Paris Cité, Inserm, Paris, France.
²² Service Hématologie, Hôpital Lyon Sud, Pierre-Bénite, France.
²³ Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva 4, Switzerland.

PMID: 37192755
DOI: 10.1111/bjh.18859

Abstract

Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high-risk relapsed/refractory Hodgkin lymphoma (R/R HL). The AETHERA study showed survival gain with Brentuximab Vedotin (BV) maintenance after ASCT in BV-naive patients, which was recently confirmed in the retrospective AMAHRELIS cohort, including a majority of BV-exposed patients. However, this approach has not been compared to intensive tandem auto/auto or auto/allo transplant strategies, which were used before BV approval. Here, we matched BV maintenance (AMAHRELIS) and tandem SCT (HR2009) cohorts, and observed that BV maintenance was associated with better survival outcome in patients with HR R/R HL.

Keywords: Hodgkin lymphoma relapse; brentuximab vedotin maintenance; long term toxicity; primary refractory disease; tandem stem cell transplantation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Brentuximab Vedotin
Cohort Studies
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease* / drug therapy
Humans
Immunoconjugates* / therapeutic use
Retrospective Studies
Stem Cell Transplantation

Substances

Brentuximab Vedotin
Immunoconjugates